Company Profile

Industry Sector: Medical Devices and Diagnostics

Company Overview: NeuroBioTex has pioneered the use of ionic zinc signals as metabolic biomarkers for diseases and disorders of brain, pancreas, and prostate. Our main mission now is diagnosing and in situ imaging of prostate cancer. Our lead product is a home test that shows about 95% PPV for the identification of prostate disease, using a sample of a man’s ejaculate, placed into a simple cup with a “dip stick.” The second device is a quantitative reference laboratory test that helps the physician recognize the presence of cancer, inflammatory changes or infection. Early intervention in these issues can lower mortality, guide treatment to arrest progression as well as reduce costs.

Target Market(s): All men over 40 have been recommended to screen annually for prostate cancer, the leading cause of cancer death among men of all races. In the USA, that is approximately 50,000,000 men.

Management

The Andro Team is highly qualified to achieve success with top zinc analytical scientists and medical device executives in the management of the company. The team is uniquely qualified to achieve success with over seventy five years of technical acumen and forty years of medical device business experience.

Leadership:
Chris Frederickson, Ph.D., CEO
Cathy Frederickson, President
John Cvinar, COO
Mike Warren, MD, CMO (Former Head, Urology, UTMB, Galveston)

Scientific Advisory Board:
John Stobo, MD Chief, University of California Medical System
Carol Fierke, PhD. Professor and Chair, Chemistry, U Michigan, Ann Arbor
HH Sandstead, MD, Professor Emeritus, UTMB, Galveston
Daryl Carney, PhD., Professor of Medicine, UTMB, Galveston & CEO Chrysalis, Inc.

Key Value Drivers

Technology: NeuroBioTex principals have over 30 person-years in the discovery and exploration of the ionic zinc signaling systems in mammals. The prostate gland has the most robust zinc signaling system known in nature, and the zinc signaling is disabled early in the emergence of carcinoma of the prostate. This makes zinc an ideal biomarker for identifying cancer (by the loss of zinc from prostatic secretions, i.e. semen). Moreover, we have near infra red fluorescent imaging methods that can be used to image the zinc-rich (healthy) and zinc-poor (cancerous) regions of the prostate in vivo, using a simple trans-rectal “lipstick” camera.

Competitive Advantage:
Zinc imaging and detecting is fast, simple, inexpensive, and accurate. That puts our methods ahead of more complex nucleic acid or proteomic methods.
We have the only home test for prostate cancer screening underdevelopment, and it is unlikely that another will become available in less than 10-15 years. Our multi analyte technique provides a truly accurate platform that will be challenging to duplicate or exceed.

Plan & Strategy:
Technology Funded by the NCI and being commercialized under the NIH-CAP

Product Pipeline

<table>
<thead>
<tr>
<th>Device</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference Test</td>
<td>Testing</td>
<td>FDA trial and Submission Preparation</td>
<td>Market Validation &amp; FDA Review</td>
<td>Commercial Release</td>
<td>Commercial Sale</td>
</tr>
<tr>
<td>Home Test</td>
<td>Development and Testing</td>
<td>FDA Trial and Submission Review</td>
<td>Market Validation</td>
<td>Commercial Release</td>
<td></td>
</tr>
</tbody>
</table>